Deciding whom to biopsy

Christopher Amling, William J. Catalona, Eric A. Klein

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Biopsy results from the Prostate Cancer Prevention Trial (PCPT) showed that prostate cancer exists at all PSA levels and that a significant number of men with "normal" PSA levels have high grade cancer. These findings and the low specificity of total PSA in discriminating cancer from benign disease have added to the debate about how best to use PSA in selecting men for prostate biopsy. Lower PSA thresholds for consideration of biopsy, particularly in younger men, are advocated by some. PSA velocity measurements may assist in the identification of men most likely to harbor cancer, and lower PSA velocity thresholds may be more appropriate in younger men. A more individualized approach using a predictive model developed from PCPT biopsy results is promoted by others. While able to incorporate risk variables other than PSA, including new markers, this risk calculator does not include PSA velocity since this variable was not found to have independent predictive value in this model. This article will present differing viewpoints on selecting men for prostate biopsy, one advocating the use of a PSA cut-off or PSA velocity measure (Dr. Catalona) and the other arguing for the routine use of established risk nomograms (Dr. Klein).

Original languageEnglish (US)
Pages (from-to)542-545
Number of pages4
JournalUrologic Oncology: Seminars and Original Investigations
Volume28
Issue number5
DOIs
StatePublished - Sep 2010

Fingerprint

Biopsy
Prostatic Neoplasms
Prostate
Neoplasms
Nomograms

Keywords

  • Prostate biopsy
  • Prostate cancer
  • Prostate specific antigen

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Deciding whom to biopsy. / Amling, Christopher; Catalona, William J.; Klein, Eric A.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 28, No. 5, 09.2010, p. 542-545.

Research output: Contribution to journalArticle

Amling, Christopher ; Catalona, William J. ; Klein, Eric A. / Deciding whom to biopsy. In: Urologic Oncology: Seminars and Original Investigations. 2010 ; Vol. 28, No. 5. pp. 542-545.
@article{86605524c9f94c99a23d45c402e04211,
title = "Deciding whom to biopsy",
abstract = "Biopsy results from the Prostate Cancer Prevention Trial (PCPT) showed that prostate cancer exists at all PSA levels and that a significant number of men with {"}normal{"} PSA levels have high grade cancer. These findings and the low specificity of total PSA in discriminating cancer from benign disease have added to the debate about how best to use PSA in selecting men for prostate biopsy. Lower PSA thresholds for consideration of biopsy, particularly in younger men, are advocated by some. PSA velocity measurements may assist in the identification of men most likely to harbor cancer, and lower PSA velocity thresholds may be more appropriate in younger men. A more individualized approach using a predictive model developed from PCPT biopsy results is promoted by others. While able to incorporate risk variables other than PSA, including new markers, this risk calculator does not include PSA velocity since this variable was not found to have independent predictive value in this model. This article will present differing viewpoints on selecting men for prostate biopsy, one advocating the use of a PSA cut-off or PSA velocity measure (Dr. Catalona) and the other arguing for the routine use of established risk nomograms (Dr. Klein).",
keywords = "Prostate biopsy, Prostate cancer, Prostate specific antigen",
author = "Christopher Amling and Catalona, {William J.} and Klein, {Eric A.}",
year = "2010",
month = "9",
doi = "10.1016/j.urolonc.2010.05.012",
language = "English (US)",
volume = "28",
pages = "542--545",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Deciding whom to biopsy

AU - Amling, Christopher

AU - Catalona, William J.

AU - Klein, Eric A.

PY - 2010/9

Y1 - 2010/9

N2 - Biopsy results from the Prostate Cancer Prevention Trial (PCPT) showed that prostate cancer exists at all PSA levels and that a significant number of men with "normal" PSA levels have high grade cancer. These findings and the low specificity of total PSA in discriminating cancer from benign disease have added to the debate about how best to use PSA in selecting men for prostate biopsy. Lower PSA thresholds for consideration of biopsy, particularly in younger men, are advocated by some. PSA velocity measurements may assist in the identification of men most likely to harbor cancer, and lower PSA velocity thresholds may be more appropriate in younger men. A more individualized approach using a predictive model developed from PCPT biopsy results is promoted by others. While able to incorporate risk variables other than PSA, including new markers, this risk calculator does not include PSA velocity since this variable was not found to have independent predictive value in this model. This article will present differing viewpoints on selecting men for prostate biopsy, one advocating the use of a PSA cut-off or PSA velocity measure (Dr. Catalona) and the other arguing for the routine use of established risk nomograms (Dr. Klein).

AB - Biopsy results from the Prostate Cancer Prevention Trial (PCPT) showed that prostate cancer exists at all PSA levels and that a significant number of men with "normal" PSA levels have high grade cancer. These findings and the low specificity of total PSA in discriminating cancer from benign disease have added to the debate about how best to use PSA in selecting men for prostate biopsy. Lower PSA thresholds for consideration of biopsy, particularly in younger men, are advocated by some. PSA velocity measurements may assist in the identification of men most likely to harbor cancer, and lower PSA velocity thresholds may be more appropriate in younger men. A more individualized approach using a predictive model developed from PCPT biopsy results is promoted by others. While able to incorporate risk variables other than PSA, including new markers, this risk calculator does not include PSA velocity since this variable was not found to have independent predictive value in this model. This article will present differing viewpoints on selecting men for prostate biopsy, one advocating the use of a PSA cut-off or PSA velocity measure (Dr. Catalona) and the other arguing for the routine use of established risk nomograms (Dr. Klein).

KW - Prostate biopsy

KW - Prostate cancer

KW - Prostate specific antigen

UR - http://www.scopus.com/inward/record.url?scp=77956287888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956287888&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2010.05.012

DO - 10.1016/j.urolonc.2010.05.012

M3 - Article

C2 - 20816613

AN - SCOPUS:77956287888

VL - 28

SP - 542

EP - 545

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 5

ER -